ILLUMINA, INC. ILMN
Nasdaq · XNAS · stock · Laboratory Analytical Instruments
Chart by TradingView
7/9
Piotroski F — financial health
3.04
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $4.3B | $850.0M | $2.9B | $931.0M | $2.7B |
| 2024 | $4.4B | -$1.2B | $2.9B | $709.0M | $2.4B |
| 2023 | $4.5B | -$1.2B | $2.7B | $283.0M | $5.7B |
| 2023 | $4.6B | -$4.4B | $3.0B | $106.0M | $6.6B |
| 2022 | $4.5B | $762.0M | $3.2B | $337.0M | $10.7B |
| 2021 | $3.2B | $656.0M | $2.2B | $891.0M | $4.7B |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.04 (safe)
- Working capital / assets 0.256
- Retained earnings / assets -0.059
- EBIT / assets 0.121
- Equity / liabilities 0.694
Source: SEC EDGAR filings · CIK 0001110803 · as of 2025-12-28. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.